Compositions and methods for targeting dendritic cell lectins
AssigneesMassachusetts Institute of Technology, Georgia Tech Research Corporation
InventorsValerie LENSCH, Laura L. KIESSLING, Mohammad Murshid ALAM, M. G. FINN, Robert HINCAPIE
Life of this patent
Estimating the term…
Abstract
Compositions and methods of glycosylated virus-like particles (VLPs) displaying user-defined antigens and optionally encapsidating TLR ligands for targeting dendritic cell lectins have been developed. The VLPs employ ligands for a DC lectin e.g., DC-SIGN to activate dendritic cells (DC) and drive proliferation of antigen-specific CD8 and CD4-T cells specific for a user-defined antigen, such as a tumor antigens. In some forms, the compositions include aryl-mannose ligands to effectively generate DC-mediated TH-1 T cell responses to the user-defined antigen.
Claims50
A composition for antigen-specific activation of dendritic cells, comprising
- (a) synthetic Virus Like Particles (VLPs);
- (b) one or more species of DC-SIGN ligand(s);
- and
- (c) two or more species of peptide antigen(s),
- wherein the DC-SIGN ligand(s) and the antigen(s) are displayed at the outer surface of the synthetic VLP.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.